Precision For Medicine’s Post

View organization page for Precision For Medicine, graphic

134,647 followers

Precision's Anshul Mangal weighs in on what to expect in 2024 regarding biopharma manufacturing and supply-related issues in this Scrip Asks Part 3 series. "Cell and gene therapies will continue to dominate the innovative clinical pipeline with the largest number of treatments in clinical trials (589 gene therapies and 568 cell therapies). The recent historic landmark of the first CRISPR technology gaining regulatory approval signals confidence in this approach. Additionally, as the adoption of radioligand therapy increases, it continues to show profound potential. One of the most promising aspects of radioligand therapy lies in the potential to create unique combinations of radioactive atoms and targeting molecules tailored to specific tumor types." Read the article here (subscription required): https://hubs.ly/Q02jhKP30 #precisionmedicine #biopharma #clinicaltrials

Scrip Asks…What Does 2024 Hold For Biopharma? Part 3: Manufacturing And Supply (Subscription required)

Scrip Asks…What Does 2024 Hold For Biopharma? Part 3: Manufacturing And Supply (Subscription required)

scrip.citeline.com

To view or add a comment, sign in

Explore topics